Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Roche
|
| gptkbp:acquisitionYear |
2023
|
| gptkbp:CEO |
gptkb:Stéphane_Bancel
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
gptkb:GLP-1_receptor_agonists
dual GLP-1/GIP receptor agonists |
| gptkbp:focusesOn |
gptkb:diabetes
obesity metabolic diseases |
| gptkbp:foundedYear |
2008
|
| gptkbp:headquartersLocation |
gptkb:Berkeley,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Carmot Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
CT-388
CT-868 CT-996 |
| gptkbp:platform |
Chemotype Evolution
|
| gptkbp:website |
https://www.carmot.us/
|
| gptkbp:bfsParent |
gptkb:The_Column_Group
gptkb:Versant_Ventures |
| gptkbp:bfsLayer |
7
|